Showing results (91-100 of 149) with videos related to
Sort By:
Pageof 15
Cancer|June 24, 2010
Activity and tolerability of nilotinib: a retrospective multicenter analysis of chronic myeloid leukemia patients who are imatinib resistant or intolerantMaya Koren-Michowitz, Philipp le Coutre, Justus Duyster, et al.Journal of Neurosurgery|November 26, 2014
Conflicting pathology reports: a diagnostic dilemmaTal Shahar, Uri Rozovski, Yuval Shapira, et al.Journal of Oncology|September 23, 2020
Tyrosine Kinase Inhibitors as a Treatment of Symptomatic CNS Metastases in Oncogene-Driven NSCLCOmer Gal, Elizabeth Dudnik, Ofer Rotem, et al.Journal of Neuro-Oncology|March 12, 2025
Long-term impact of bevacizumab for the treatment of brain radiation necrosisHila Nobel, Jonathan Ofer, Sara Faye Borenstein, et al.Neuro-Oncology Advances|October 21, 2024
A phase II, open-label, single-arm trial of pembrolizumab for recurrent meningioma and solitary fibrous tumorDror Limon, Alexandra Amiel, Shaked Even Haim, et al.Neuro-Oncology Advances|October 30, 2024
Effect of bevacizumab on refractory meningiomas: 3D volumetric growth rate versus response assessment in neuro-oncology criteriaSara Faye Borenstein, Ruth Eliahou, Alexandra Amiel, et al.Anticancer Research|February 11, 2014
Hodgkin's variant of Richter transformation in chronic lymphocytic leukemia; a retrospective study from the Israeli CLL study groupTamar Tadmor, Lev Shvidel, Neta Goldschmidt, et al.American Journal of Hematology|August 12, 2014
Richter's transformation to diffuse large B-cell lymphoma: a retrospective study reporting clinical data, outcome, and the benefit of adding rituximab to chemotherapy, from the Israeli CLL Study GroupTamar Tadmor, Lev Shvidel, Osnat Bairey, et al.Leukemia & Lymphoma|February 15, 2014
Polymorphisms in the human organic cation transporter and the multidrug resistance gene: correlation with imatinib levels and clinical course in patients with chronic myeloid leukemiaJacob Vine, Sara Bar Cohen, Rosa Ruchlemer, et al.Annals of Hematology|August 23, 2016
Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocolMoshe Mittelman, Kalman Filanovsky, Yishai Ofran, et al.Pageof 15